Compare Abbott Laboratories (ABT) vs EHang Holdings Ltd - ADR (EH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs EHang Holdings Ltd - ADR — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while EHang Holdings Ltd - ADR trades at $5.63 (market cap $417.53M). The key difference: Abbott Laboratories is far larger — about 399.8× EHang Holdings Ltd - ADR's market cap, and Abbott Laboratories pays a 2.63% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals.
| ABT | EH | |
|---|---|---|
Market Cap | $166.94B | $417.53M |
Sector | Health | Industrials |
52-Week High | $136.62 | $19.99 |
52-Week Low | $82.57 | $5.52 |
Enterprise Value | $193.69B | $357.19M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
EHang Holdings trades at $5.52, down 12.52% over 24 hours, reflecting bearish technical signals and weak quarterly earnings. The company reported a net loss of $275.98 million for 2025 with a -77.56% net margin, though revenue reached $417.98 million. Recent news highlights volatility, including an 18% surge on June 15, 2026, following a Q1 2026 earnings miss reported by The Motley Fool on June 9, 2026.
The outlook remains challenged by persistent losses and high cash burn, but analyst consensus suggests moderate upside with a $7.75 price target. Key risks include execution delays in eVTOL commercialization and reliance on financing amid negative cash flows, while institutional sentiment is mixed with 40% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →
